Sujay Kango Net Worth

The estimated Net Worth of Sujay Kango is at least $7 Million dollars as of 27 September 2021. Mr. Kango owns over 5,000 units of Acceleron Pharma Inc stock worth over $4,202,234 and over the last 10 years he sold XLRN stock worth over $1,430,447. In addition, he makes $1,366,060 as Executive Vice President and Chief Commercial Officer at Acceleron Pharma Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Kango XLRN stock SEC Form 4 insiders trading

Sujay has made over 7 trades of the Acceleron Pharma Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 5,000 units of XLRN stock worth $203,050 on 27 September 2021.

The largest trade he's ever made was selling 75,000 units of Acceleron Pharma Inc stock on 12 December 2016 worth over $96,000. On average, Sujay trades about 4,594 units every 80 days since 2015. As of 27 September 2021 he still owns at least 23,509 units of Acceleron Pharma Inc stock.

You can see the complete history of Mr. Kango stock trades at the bottom of the page.

Sujay Kango biography

Sujay R. Kango serves as Executive Vice President and Chief Commercial Officer of the Company. He joined Acceleron in February 2018 and is currently our Executive Vice President and Chief Commercial Officer. Mr. Kango previously served as Vice President, Oncology Global Commercial at AbbVie Inc. from January 2017 through February 2018, and as Executive Vice President and Chief Commercial Officer at Infinity Pharmaceuticals, Inc. from April 2015 through January 2017. Prior to that, Mr. Kango served from April 2011 to March 2015 as Vice President, Global Marketing, Sales Operations, and Business Analytics at Onyx Pharmaceuticals, an Amgen subsidiary and a pharmaceutical company, where he led the global Onyx proteasome inhibitor franchise, including Kyprolis® and oprozomib and co-chaired the Onyx-Bayer executive committee responsible for oversight of the companies’ global kinase inhibitor franchise. Prior to Onyx, from January 2006 to March 2011, he held several leadership positions at Merck & Co., a pharmaceutical company, including vice president, hepatitis franchise and vice president, oncology integrated business unit. Prior to Merck, from November 1990 to May 2005, Mr. Kango held various commercial and marketing roles of increasing responsibility at Johnson & Johnson and Schering-Plough, each of which is a pharmaceutical company. Mr. Kango earned a B.S. in Microbiology and an M.B.A. from McNeese State University.

What is the salary of Sujay Kango?

As the Executive Vice President and Chief Commercial Officer of Acceleron Pharma Inc, the total compensation of Sujay Kango at Acceleron Pharma Inc is $1,366,060. There are 2 executives at Acceleron Pharma Inc getting paid more, with Habib Dable having the highest compensation of $4,273,090.

How old is Sujay Kango?

Sujay Kango is 56, he's been the Executive Vice President and Chief Commercial Officer of Acceleron Pharma Inc since 2018. There are 8 older and 3 younger executives at Acceleron Pharma Inc. The oldest executive at Acceleron Pharma Inc is Jay Backstrom, 65, who is the Executive Vice President - Research and Development.

Insiders trading at Acceleron Pharma Inc

Over the last 11 years, insiders at Acceleron Pharma Inc have traded over $211,038,855 worth of Acceleron Pharma Inc stock and bought 4,435,573 units worth $172,392,007 . The most active insiders traders include Corp /De/ Celgene, Richard F Pops, and Anthony B Evnin. On average, Acceleron Pharma Inc executives and independent directors trade stock every 10 days with the average trade being worth of $7,646,210. The most recent stock trade was executed by Adam M Veness on 9 November 2021, trading 4,500 units of XLRN stock currently worth $132,165.

What does Acceleron Pharma Inc do?

Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron's leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.

Complete history of Mr. Kango stock trades at Acceleron Pharma Inc, Infinity Pharmaceuticals, and MEI Pharma Inc

Acceleron Pharma Inc executives and stock owners

Acceleron Pharma Inc executives and other stock owners filed with the SEC include:

• Habib Dable,
  President, Chief Executive Officer, Director
• Kevin McLaughlin,
  Chief Financial Officer, Senior Vice President, Treasurer
• Sujay Kango,
  Executive Vice President and Chief Commercial Officer
• Ravindra Kumar,
  Senior Vice President, Chief Scientific Officer
• Francois Nader,
  Independent Chairman of the Board
• Joseph Zakrzewski,
  Independent Director
• Terrence Kearney,
  Independent Director
• Thomas McCourt,
  Independent Director
• Karen Smith,
  Independent Director
• Todd James,
  Senior Vice President Corporate Affairs and Investor Relations
• Kemal Malik,
  Independent Director
• Christopher Hite,
  Director
• Laura Hamill,
  Director
• Jay Backstrom,
  Executive Vice President - Research and Development
• Terrance Mcguire,
  Director
• Tom Maniatis,
  Director
• Jean George,
  Director
• John L Knopf,
  CEO and President
• Steven D Ertel,
  SVP & Chief Business Officer
• Matthew L Sherman,
  SVP & Chief Medical Officer
• Richard F Pops,
  Director
• Adam M Veness,
  SVP, General Counsel and Sec.
• John D Quisel,
  EVP, Chief Business Officer
• Christopher Rovaldi,
  SVP, Program Mgmt and Ops
• Robert K Zeldin,
  EVP & Chief Medical Officer
• Corp /De/ Celgene,
  10% owner
• Anthony B Evnin,
  Director
• Edwin M Jr Kania,
  Director
• Venture Management Co Iv Ll...,
  
• Venture Management Co Iv Ll...,
  
• Advisors Llcorbimed Capital...,
  
• Corp /De/Bristol Myers Squi...,